Literature DB >> 23816638

Cognitive impairment among different clinical courses of multiple sclerosis.

Helene Brissart1, Elodie Morele, Cedric Baumann, Matthieu Le Perf, Matthieu Leininger, Laetitia Taillemite, Céline Dillier, Sophie Pittion, Elisabeth Spitz, Marc Debouverie.   

Abstract

BACKGROUND: As of yet, no consensus has been reached regarding cognitive impairment profiles in multiple sclerosis (MS) patients based on the MS type and disease duration. The main objective of this study was to describe cognitive impairment at the early stages of MS. The secondary objective was to compare cognitive performances in patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive (SP) MS and primary progressive (PP) MS.
METHODS: The study included 128 MS patients and 63 healthy controls (HC). The study constituted five groups: early RR (ERR) (<3 years); late RR (LRR) (>10 years), SP, PP, and healthy Controls (HC). A neuropsychological assessment was performed including information processing speed (IPS), working memory, verbal episodic memory and executive functions.
RESULTS: Compared to HC, only impairment in phonemic fluency was observed in ERR. Slowing IPS, impairment in working memory and phonemic fluency were shown in LRR. In progressive forms, deficits were observed in verbal episodic memory, in working memory, in flexibility, in semantic and phonemic fluencies, with a slowing IPS.
CONCLUSION: Verbal fluency is impaired at early stage of RRMS, in this form of MS, impairment increased with MS duration, and distinct cognitive profiles were observed between chronic and progressive forms.

Entities:  

Mesh:

Year:  2013        PMID: 23816638     DOI: 10.1179/1743132813Y.0000000232

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  10 in total

1.  Emotional Intelligence (EI) of Patients with Multiple Sclerosis (MS).

Authors:  Mahsa Ghajarzadeh; Mahsa Owji; Mohammad Ali Sauraian; Abdorreza Naser Moghadasi; Amirreza Azimi
Journal:  Iran J Public Health       Date:  2014-11       Impact factor: 1.429

2.  The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI.

Authors:  Céline Louapre; Sindhuja T Govindarajan; Costanza Giannì; Nancy Madigan; A Scott Nielsen; Jacob A Sloane; Revere P Kinkel; Caterina Mainero
Journal:  Neuroimage Clin       Date:  2016-11-03       Impact factor: 4.881

3.  Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.

Authors:  Tobias V Lanz; Sarah K Williams; Aleksandar Stojic; Simeon Iwantscheff; Jana K Sonner; Carl Grabitz; Simon Becker; Laura-Inés Böhler; Soumya R Mohapatra; Felix Sahm; Günter Küblbeck; Toshikazu Nakamura; Hiroshi Funakoshi; Christiane A Opitz; Wolfgang Wick; Ricarda Diem; Michael Platten
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

4.  Learning ability correlates with brain atrophy and disability progression in RRMS.

Authors:  Maria Pia Sormani; Nicola De Stefano; Gavin Giovannoni; Dawn Langdon; Daniela Piani-Meier; Dieter A Haering; Ludwig Kappos; Davorka Tomic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-15       Impact factor: 10.154

Review 5.  Cognitive Dysfunction in the Early Stages of Multiple Sclerosis-How Much and How Important?

Authors:  Magdalena Oset; Mariusz Stasiolek; Mariola Matysiak
Journal:  Curr Neurol Neurosci Rep       Date:  2020-05-22       Impact factor: 5.081

6.  An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI).

Authors:  Tehila Eilam-Stock; Pamela Best; Kathleen Sherman; Michael T Shaw; Joseph Ventura; Lauren B Krupp; Leigh E Charvet
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

Review 7.  Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype.

Authors:  Bruno Brochet; Pierre Clavelou; Gilles Defer; Jérôme De Seze; Céline Louapre; Eloi Magnin; Aurélie Ruet; Catherine Thomas-Anterion; Patrick Vermersch
Journal:  Brain Sci       Date:  2022-01-29

8.  Changes in disability in people with multiple sclerosis: a 10-year prospective study.

Authors:  David Conradsson; Charlotte Ytterberg; Lena von Koch; Sverker Johansson
Journal:  J Neurol       Date:  2017-11-20       Impact factor: 4.849

9.  Phototest for neurocognitive screening in multiple sclerosis.

Authors:  Joana Pinto; Emanuela Lopes; Gerly Gonçalves; Ângela Silva; Bruno Peixoto
Journal:  Dement Neuropsychol       Date:  2016 Jan-Mar

Review 10.  Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.

Authors:  Elzbieta Miller; Agnieszka Morel; Justyna Redlicka; Igor Miller; Joanna Saluk
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.